Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Coswig – page 12

1 038 clinical trials in Coswig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Coswig at a glance
1 038
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 038 trials in Coswig

Open in trial search

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Novartis Pharma AG

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Coswig

What the registry says about research in the country

01 Pulmonary Fibrosis Research

Ongoing clinical trials focusing on Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF), evaluating innovative inhaled treatments to improve lung function and patient outcomes.

  • Inhaled Treprostinil Studies
  • Long-term Safety Evaluations
  • FVC Measurements

Multiple Phase 3 studies are examining both short and long-term treatment effects in patients with fibrotic conditions.

02 Interstitial Lung Disease Studies

Research initiatives targeting Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), with trials designed to assess new therapeutic approaches for reducing lung function decline.

  • Novel Drug Evaluations
  • Disease Progression Monitoring
  • Treatment Safety Assessments

Comprehensive studies examining both established and experimental treatments for various forms of lung fibrosis.

03 Advanced Therapeutic Development

Investigation of new compounds including bexotegrast and other innovative medications for treating various forms of pulmonary fibrosis and related conditions.

  • Placebo-controlled Studies
  • Efficacy Measurements
  • Long-term Treatment Effects

Multiple parallel studies are evaluating different therapeutic approaches to address various manifestations of fibrotic lung disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.